Disease-modifying antirheumatic drugs (DMARDs) did not offer clinically significant pain relief compared to placebo for patients with osteoarthritis (OA), according to a study published online in the journal Rheumatology. 

Researchers reviewed Medline, Embase, Allied and Complementary Medicine Database, Web of Science, and Cochrane Library, as well as conference abstracts and ClinicalTrials.gov information to identify randomized, controlled trials (RCTs) of DMARDs and placebo for symptomatic OA published through November 2017. They included 11 RCTs with 1,205 participants, including six with conventional DMARDs (n = 757) and five with biologics (n = 448). DMARDs were statistically superior to placebo, but not clinically significant. The researchers did not observe statistically significant differences in subanalysis of high-quality trials, biologics, or conventional DMARDs. Learn more...

Submit Community Content

If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!